Rapid PSA rise may point to high risk of prostate cancer death
July 23rd 2004Men whose PSA level increases by more than 2.0 ng/mL during the year prior to a prostate cancer diagnosis may have a relatively high risk of future cancer death even if they undergo radical prostatectomy, according to a recent report in the New England Journal of Medicine (2004; 351:125-35).
Survivors of prostate Ca are second largest group of cancer survivors
July 8th 2004Prostate cancer survivors are the second largest group of cancer survivors in the United States, following breast cancer survivors as the largest group, according to a report by the Centers for Disease Control and Prevention and the National Cancer Institute.
Stem cell therapy may 'cure' stress urinary incontinence
July 1st 2004San Francisco--Stem cell therapy can repair the tissue damage that causes urinary incontinence, say Austrian researchers, who used myoblasts and fibroblasts to strengthen patients' rhabdosphincters and urethras and eliminate their symptoms.
Therapeutic options for sexual dysfunction still growing
July 1st 2004Do you think the three available phosphodiesterase type-5 inhibitors-vardenafil hydrochloride (Levitra), tadalafil (Cialis), and sildenafil citrate (Viagra)-are essentially the same, or do they have distinct advantages in the treatment of ED?
Antibiotic, alpha-blocker ineffective for CP/CPPS
July 1st 2004San Francisco--A commonly prescribed antibiotic and alpha-blocker appear to be ineffective in the treatment of men with moderate to severe chronic prostatitis/chronic pelvic pain syndrome of long duration. Results of a multicenter study found that both ciprofloxacin and tamsulosin-used primarily in the treatment of urinary tract infections and BPH, respectively-offered no significant benefit in the treatment of chronic prostatitis in patients who were heavily pretreated and had long-standing symptoms.
CMS, NCI to prioritize cancer research, improve drug approval process
June 24th 2004The Centers for Medicare & Medicaid Services and the National Cancer Institute have developed a joint Memorandum of Understanding to address how the two agencies can work together in five areas of technology, science, and patient care for cancer.